SIM
VIR icon

SummerHaven Investment Management’s Vir Biotechnology VIR Stock Holding History

SummerHaven Investment Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,312
Closed -$523K – 265
2023
Q2 		$523K Sell
21,312
-4,733
-18% -$119K 0.33% 158
2023
Q1 		$606K Buy
26,045
+702
+3% +$18K 0.35% 166
2022
Q4 		$641K Buy
25,343
+416
+2% +$10.2K 0.38% 168
2022
Q3 		$481K Buy
+24,927
New +$634K 0.33% 196

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SummerHaven Investment Management's VIR Position: Q3 2023 in Review

SummerHaven Investment Management sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 21,312 shares — an estimated $523K sold.

SummerHaven Investment Management first reported a position in VIR in Q3 2022 and held it in 4 quarters. The position peaked at $641K in Q4 2022. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • SummerHaven Investment Management reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • SummerHaven Investment Management sold 21,312 Vir Biotechnology shares in Q3 2023, an estimated $523K.
  • SummerHaven Investment Management first reported a position in Vir Biotechnology in Q3 2022 and held it in 4 quarters.
  • SummerHaven Investment Management's Vir Biotechnology position peaked at $641K in Q4 2022.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on SummerHaven Investment Management's 13F filing for Q3 2023, filed 13 Oct 2023.